Document is current
Any future updates will be listed below
-
Authors
Kester, Robert
Zalani, Sunita
Ebbinghaus, Scot
Rubin, Eric
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Accepted: 10 October 2024
First Online: 13 November 2024
Declarations
:
: Study funding was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).
: RK, SZ, and SE are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD) and may hold stock in Merck & Co., Inc., Rahway, NJ, USA. Eric Rubin has since retired from employment at MSD.
: Not applicable.
: Not applicable.
: Not applicable.
: All data on oncology drug approvals collated in this review article are publicly available and are also included in this article (and its supplementary information files).
: Not applicable.
: SZ conceived of the idea for the publication; RK performed the literature search and data analysis and acted as the lead and corresponding author. RK and SZ drafted the original manuscript, and all authors critically reviewed all sections of the manuscript and approved the final draft for submission.
